Stem Cells In-Depth Focus 2017
Posted: 5 June 2017 | Drug Target Review | No comments yet
Included in this Stem Cells In-Depth Focus: Translating discoveries into therapies; The key to successful manufacturing of patient-specific cell therapies; Interview with Alessandro Prigione and James Adjaye…
Advances in cell therapy can present unique challenges, especially as more products move out of the clinic and toward commercialisation.
In our new Stem Cells In-Depth Focus, Brian Hampson and David Smith explain Development by Design – a manufacturing strategy for cell therapies that considers quality, scalability, sustainability, and cost of goods sold.
In addition, Drug Target Review Editor Steve Bremer discusses stem cell use with leading scientists working in drug discovery.
Finally, Prof Dr James Adjaye and Dr Alessandro Prigione explain how they use stem cells in their research, and the issues this raises.
This Stem Cells In-Depth Focus is restricted - login or subscribe free to access
Thank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.
Why subscribe? Join our growing community of thousands of industry professionals and gain access to:
- quarterly issues in print and/or digital format
- case studies, whitepapers, webinars and industry-leading content
- breaking news and features
- our extensive online archive of thousands of articles and years of past issues
- ...And it's all free!
Click here to Subscribe today Login here
Related topics
Oncology, Stem Cells, Therapeutics
Related conditions
cell therapy
Related organisations
Institute for Stem Cell Research and Regenerative Medicine, Max Delbrück Centre for Molecular Medicine, Progenitor Cell Therapy (PCT), Takara Bio
Related people
Alessandro Prigione, Brian Hampson, David Smith, Prof Dr James Adjaye